Narayana Hrudayalaya Ltd Q1 FY27 Earnings Analysis

- Clinic business to be integrated with hospital business from FY27, reflecting better contribution measurement. - Focus on domestic patients to replace international patient volumes, with no active international marketing currently. - Investment in digital marketing, integrated care, clinics, insurance, and strengthening clinical teams expected to drive volume growth in Eastern region within 2-3 quarters. - No immediate expansion plans in North and West clusters; focus on expanding adult programs in existing Mumbai SRCC hospital. - Clinics serve as initial patient contact points, expected to shift patient preference from hospitals to clinics, supporting hospital expansion. - ARPP (Average Revenue per Patient) growth anticipated through advanced procedures and case mix optimization. - Growth in volumes expected with ongoing investments in clinics, digital marketing, and insurance over coming quarters. - Incremental volume growth projections to ultimately cover current growth deficits observed in some geographies.

- Narayana Hrudayalaya is in an expansion phase, investing heavily (USD 100 million capex; INR 3,000 crores planned in India) to fuel growth, which may dilute short-term ROCE/ROE but is expected to be accretive long-term. - EBITDA margin normalized to about 22% (excluding one-time acquisition cost impact) is the starting base, with efforts ongoing to improve margins. - Mumbai hospital broke even in Q4 and profitability is expected to improve with the adult program launch. - Clinic network expansion drives inpatient referrals, expected to underpin future growth; integration with insurance plans also fosters growth. - Growth in volumes expected but tempered by competitive and inflationary pressures; pricing increases in low to mid-single digits annually. - International businesses (UK, Cayman) are still stabilizing; cost rationalization and synergy realization are ongoing. - No specific EPS guidance given; focus remains on maintaining growth pace and margin improvement while managing new center losses.

- FY26 greenfield capex was INR 109 crores, lower than the planned INR 424 crores, mainly due to election-related labor shortages and delays in permissions; FY28 commissioning timeline for Rajarhat, HSR, Raipur, Bangalore still on track. - Total proposed capex for projects is INR 3,000 crores, with greenfield organic capex of INR 460 crores; expected to commission INR 1,000 crores each in FY28 and FY29. - India capex details are in the IR deck; no additional capex planned for Cayman; UK capex plans not disclosed yet. - Clinics are expanding: currently 11 clinics in Bangalore, expanding to Calcutta in FY27, aiming to double clinic numbers cautiously balancing cash losses and property acquisition. - Higher capex versus earlier models due to increased construction cost (~60% higher) and land cost particularly in cities; focus on automation and efficiency to maintain low-cost, high-quality service. - Strategic investments include AI integration for clinical data analytics and hospital operations efficiency.

Based on the transcript in the provided pages of Narayana Hrudayalaya Limited's May 26, 2026 call: - No specific mention of immediate new fundraising plans through debt or equity. - The company is currently servicing existing debt, notably a GBP 150 million 7-year loan taken for the UK acquisition, with operating cash flows from the UK business. - Capex guidance indicates significant investments: USD 100 million and INR 3,000 crores planned for expansion in India, mostly greenfield projects, suggesting funding via internal accruals or existing resources. - No additional capex planned for Cayman; UK capex plans remain undecided and will be shared when available. - The company is currently in an expansion phase, focusing on diluting ROCE temporarily for long-term return gains. - No explicit mention of new equity issuance or fresh borrowing during this period.

The provided transcript excerpts from Narayana Hrudayalaya Limited's May 26, 2026 call do not mention or provide any information related to current or expected order book or pending orders. The discussion primarily focuses on: - Financial performance including EBITDA margins and PAT. - Status and profitability of Mumbai hospital and other expansions. - Insurance business performance. - Details on UK and Cayman operations, capex plans, and operational efficiencies. - Questions on ARPOB, occupancy, and cost structures. No data regarding order books or pending orders is disclosed in the provided pages.